Compare USLM & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | ICUI |
|---|---|---|
| Founded | 1948 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | N/A | 1992 |
| Metric | USLM | ICUI |
|---|---|---|
| Price | $104.00 | $142.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $179.50 |
| AVG Volume (30 Days) | 96.2K | ★ 252.1K |
| Earning Date | 02-02-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ 23.22 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | $372,727,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $13.29 | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $23.07 | ★ N/A |
| Revenue Growth | ★ 17.31 | N/A |
| 52 Week Low | $80.47 | $107.00 |
| 52 Week High | $137.96 | $165.17 |
| Indicator | USLM | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 28.97 | 38.42 |
| Support Level | $106.31 | $148.71 |
| Resistance Level | $110.28 | $155.90 |
| Average True Range (ATR) | 5.13 | 5.23 |
| MACD | -1.77 | -0.95 |
| Stochastic Oscillator | 9.06 | 12.24 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.